Furthermore, forced expression of miR-30b substantially improved tumor suppressor gene p53 expression via inhibition of MDM2, which also significantly enhanced the effect of Ad-p53 gene therapy, suggesting that miR-30b might be a novel therapeutic strategy for the treatment of laryngeal carcinoma. This evidence concerns the gene TP53 and laryngeal carcinoma.